These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 32235588)

  • 1. Preclinical Study Using ABT263 to Increase Enzalutamide Sensitivity to Suppress Prostate Cancer Progression Via Targeting BCL2/ROS/USP26 Axis Through Altering ARv7 Protein Degradation.
    Xu H; Sun Y; Huang CP; You B; Ye D; Chang C
    Cancers (Basel); 2020 Mar; 12(4):. PubMed ID: 32235588
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Preclinical studies using cisplatin/carboplatin to restore the Enzalutamide sensitivity via degrading the androgen receptor splicing variant 7 (ARv7) to further suppress Enzalutamide resistant prostate cancer.
    Chou FJ; Lin C; Tian H; Lin W; You B; Lu J; Sahasrabudhe D; Huang CP; Yang V; Yeh S; Niu Y; Chang C
    Cell Death Dis; 2020 Nov; 11(11):942. PubMed ID: 33139720
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Preclinical study using circular RNA 17 and micro RNA 181c-5p to suppress the enzalutamide-resistant prostate cancer progression.
    Wu G; Sun Y; Xiang Z; Wang K; Liu B; Xiao G; Niu Y; Wu D; Chang C
    Cell Death Dis; 2019 Jan; 10(2):37. PubMed ID: 30674872
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The miR-361-3p increases enzalutamide (Enz) sensitivity via targeting the ARv7 and MKNK2 to better suppress the Enz-resistant prostate cancer.
    Liu B; Sun Y; Tang M; Liang C; Huang CP; Niu Y; Wang Z; Chang C
    Cell Death Dis; 2020 Sep; 11(9):807. PubMed ID: 32978369
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A novel inhibitor of ARfl and ARv7 induces protein degradation to overcome enzalutamide resistance in advanced prostate cancer.
    Li Y; Chu Y; Shi G; Wang X; Ye W; Shan C; Wang D; Zhang D; He W; Jiang J; Ma S; Han Y; Zhao Z; Du S; Chen Z; Li Z; Yang Y; Wang C; Xu X; Wu H
    Acta Pharm Sin B; 2022 Nov; 12(11):4165-4179. PubMed ID: 36386477
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Preclinical studies show using enzalutamide is less effective in docetaxel-pretreated than in docetaxel-naïve prostate cancer cells.
    Lin C; Chou FJ; Lu J; Lin W; Truong M; Tian H; Sun Y; Luo J; Yang R; Niu Y; Nadal R; Antonarakis ES; Cordon-Cardo C; Sahasrabudhe D; Huang CP; Yeh S; Li G; Chang C
    Aging (Albany NY); 2020 Sep; 12(17):17694-17712. PubMed ID: 32920545
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The MAO inhibitors phenelzine and clorgyline revert enzalutamide resistance in castration resistant prostate cancer.
    Wang K; Luo J; Yeh S; You B; Meng J; Chang P; Niu Y; Li G; Lu C; Zhu Y; Antonarakis ES; Luo J; Huang CP; Xu W; Chang C
    Nat Commun; 2020 Jun; 11(1):2689. PubMed ID: 32483206
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Senolytic compounds control a distinct fate of androgen receptor agonist- and antagonist-induced cellular senescent LNCaP prostate cancer cells.
    Pungsrinont T; Sutter MF; Ertingshausen MCCM; Lakshmana G; Kokal M; Khan AS; Baniahmad A
    Cell Biosci; 2020; 10():59. PubMed ID: 32351687
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Increased chromatin accessibility mediated by nuclear factor I drives transition to androgen receptor splice variant dependence in castration-resistant prostate cancer.
    Poluben L; Nouri M; Liang J; Varkaris A; Ersoy-Fazlioglu B; Voznesensky O; Lee II; Qiu X; Cato L; Seo JH; Freedman ML; Sowalsky AG; Lack NA; Corey E; Nelson PS; Brown M; Long HW; Russo JW; Balk SP
    bioRxiv; 2024 Jun; ():. PubMed ID: 38260576
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prognostic implication of heterogeneity and trajectory progression induced by enzalutamide in prostate cancer.
    Feng Y; Deng Y; Tang Z; Cai S; Li J; Liu R; Wan J; He H; Zeng G; Ye J; Han Z; Zhong W
    Front Endocrinol (Lausanne); 2023; 14():1148898. PubMed ID: 37008945
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeting the Hsp40/Hsp70 Chaperone Axis as a Novel Strategy to Treat Castration-Resistant Prostate Cancer.
    Moses MA; Kim YS; Rivera-Marquez GM; Oshima N; Watson MJ; Beebe KE; Wells C; Lee S; Zuehlke AD; Shao H; Bingman WE; Kumar V; Malhotra SV; Weigel NL; Gestwicki JE; Trepel JB; Neckers LM
    Cancer Res; 2018 Jul; 78(14):4022-4035. PubMed ID: 29764864
    [TBL] [Abstract][Full Text] [Related]  

  • 12. ARv7 Represses Tumor-Suppressor Genes in Castration-Resistant Prostate Cancer.
    Cato L; de Tribolet-Hardy J; Lee I; Rottenberg JT; Coleman I; Melchers D; Houtman R; Xiao T; Li W; Uo T; Sun S; Kuznik NC; Göppert B; Ozgun F; van Royen ME; Houtsmuller AB; Vadhi R; Rao PK; Li L; Balk SP; Den RB; Trock BJ; Karnes RJ; Jenkins RB; Klein EA; Davicioni E; Gruhl FJ; Long HW; Liu XS; Cato ACB; Lack NA; Nelson PS; Plymate SR; Groner AC; Brown M
    Cancer Cell; 2019 Mar; 35(3):401-413.e6. PubMed ID: 30773341
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dose modification in enzalutamide and abiraterone plus prednisolone for castration-resistant prostate cancer: A subanalysis from the ENABLE study for PCa.
    Tanaka N; Izumi K; Nakai Y; Shima T; Kato Y; Mita K; Kamiyama M; Inoue S; Hoshi S; Okamura T; Yoshio Y; Enokida H; Chikazawa I; Kawai N; Hashimoto K; Fukagai T; Shigehara K; Takahara S; Mizokami A
    Prostate; 2025 Jan; 85(1):21-29. PubMed ID: 39301921
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Castration-resistant prostate cancer: Androgen receptor inactivation induces telomere DNA damage, and damage response inhibition leads to cell death.
    Reddy V; Iskander A; Hwang C; Divine G; Menon M; Barrack ER; Reddy GP; Kim SH
    PLoS One; 2019; 14(5):e0211090. PubMed ID: 31083651
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Enzalutamide-Resistant Progression of Castration-Resistant Prostate Cancer Is Driven via the JAK2/STAT1-Dependent Pathway.
    Luo Y; Yang X; Basourakos SP; Zuo X; Wei D; Zhao J; Li M; Li Q; Feng T; Guo P; Jiang Y
    Front Mol Biosci; 2021; 8():652443. PubMed ID: 34746227
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Transcript Levels of Androgen Receptor Variant 7 and Ubiquitin-Conjugating Enzyme 2C in Hormone Sensitive Prostate Cancer and Castration-Resistant Prostate Cancer.
    Lee CH; Ku JY; Ha JM; Bae SS; Lee JZ; Kim CS; Ha HK
    Prostate; 2017 Jan; 77(1):60-71. PubMed ID: 27550197
    [TBL] [Abstract][Full Text] [Related]  

  • 17. MLL5α activates AR/NDRG1 signaling to suppress prostate cancer progression.
    Quan Y; Cui Y; Wahafu W; Liu Y; Ping H; Zhang X
    Am J Cancer Res; 2020; 10(5):1608-1629. PubMed ID: 32509400
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Preclinical study using androgen receptor (AR) degradation enhancer to increase radiotherapy efficacy via targeting radiation-increased AR to better suppress prostate cancer progression.
    Chou FJ; Chen Y; Chen D; Niu Y; Li G; Keng P; Yeh S; Chang C
    EBioMedicine; 2019 Feb; 40():504-516. PubMed ID: 30692044
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Resveratrol enhances polyubiquitination-mediated ARV7 degradation in prostate cancer cells.
    Wilson S; Cavero L; Tong D; Liu Q; Geary K; Talamonti N; Xu J; Fu J; Jiang J; Zhang D
    Oncotarget; 2017 Aug; 8(33):54683-54693. PubMed ID: 28903374
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bardoxolone-Methyl (CDDO-Me) Suppresses Androgen Receptor and Its Splice-Variant AR-V7 and Enhances Efficacy of Enzalutamide in Prostate Cancer Cells.
    Khurana N; Chandra PK; Kim H; Abdel-Mageed AB; Mondal D; Sikka SC
    Antioxidants (Basel); 2020 Jan; 9(1):. PubMed ID: 31940946
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.